Grifols, S.A. - American Depositary Shares (GRFS)
GRFS moved a median of -0.13% 30 minutes after news, and +0.19% by the close. How GRFS actually reacts to news — the realized, point-in-time move the market made, measured across 300 labeled events over the last three years with zero look-ahead.
GRFS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.06% | 34% | 298 |
| 30-min | -0.13% | 39% | 298 |
| 60-min | -0.13% | 45% | 298 |
| to close | +0.19% | 54% | 294 |
| Middle 50% of GRFS reactions | -0.56% to +0.42% |
|---|---|
| Median reaction (30-min) | -0.13% |
| Measured reactions | 300 |
Half of all Grifols, S.A. - American Depositary Shares news events land between -0.56% and +0.42% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How GRFS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 12 | +0.06% | 50% | -0.94% |
| Analyst downgrades | 14 | -0.06% | 43% | -0.58% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how GRFS ranks against every other measured name →
That’s how GRFS usually reacts — get an email when it moves on news →Email me when GRFS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GRFS's baseline. Nothing else.
Recent GRFS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency | Press release | GlobeNewswire | +0.00% | — | |
| Form 6-K Grifols SA For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.32% | |
| Form 6-K Grifols SA For: Jul 28 | SEC filing · Form 6-K | SEC EDGAR | -0.36% | -1.45% | |
| Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins | Press release | GlobeNewswire | +0.14% | +1.38% | |
| Form 6-K Grifols SA For: Jun 22 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.21% | |
| Form 6-K Grifols SA For: Jun 18 | SEC filing · Form 6-K | SEC EDGAR | +0.27% | -1.35% | |
| Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. | Press release | GlobeNewswire | -0.65% | -1.42% | |
| Form 6-K Grifols SA For: May 15 | SEC filing · Form 6-K | SEC EDGAR | +0.26% | +0.66% | |
| Form 6-K Grifols SA For: May 07 | SEC filing · Form 6-K | SEC EDGAR | -0.18% | -1.17% | |
| Form 20-F Grifols SA For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | +0.12% | -1.17% | |
| Form 6-K Grifols SA For: Apr 14 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.57% | |
| Form 6-K Grifols SA For: Mar 24 | SEC filing · Form 6-K | SEC EDGAR | +0.91% | +0.39% | |
| Grifols Shares Results From its Chronos Platform Identifying Early Molecular Changes Associated with Parkinson’s Disease | Press release | GlobeNewswire | -0.25% | +0.00% | |
| Form 6-K Grifols SA For: Feb 26 | SEC filing · Form 6-K | SEC EDGAR | -0.06% | -0.50% | |
| Form 6-K Grifols SA For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | -0.05% | +0.65% | |
| Form 6-K Grifols SA For: Dec 16 | SEC filing · Form 6-K | SEC EDGAR | -0.14% | -1.21% | |
| Form 6-K Grifols SA For: Nov 04 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -1.39% | |
| Form 6-K Grifols SA For: Sep 29 | SEC filing · Form 6-K | SEC EDGAR | +1.41% | -0.30% | |
| Form 6-K Grifols SA For: Jul 30 | SEC filing · Form 6-K | SEC EDGAR | +0.05% | -0.14% | |
| Form 6-K Grifols SA For: Jul 29 | SEC filing · Form 6-K | SEC EDGAR | -0.40% | — | |
| Form 6-K Grifols SA For: Jun 11 | SEC filing · Form 6-K | SEC EDGAR | -0.33% | -0.88% | |
| Form 6-K Grifols SA For: Jun 05 | SEC filing · Form 6-K | SEC EDGAR | +0.17% | +0.17% | |
| Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting | Press release | Business Wire | -0.12% | -1.43% | |
| Form 6-K Grifols SA For: May 12 | SEC filing · Form 6-K | SEC EDGAR | +0.65% | +0.46% | |
| Form 6-K Grifols SA For: May 06 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.21% | |
| Form 6-K Grifols SA For: May 02 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.96% | |
| Form 20-F Grifols SA For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -0.87% | +1.16% | |
| Form 6-K Grifols SA For: Apr 02 | SEC filing · Form 6-K | SEC EDGAR | +0.13% | -5.45% | |
| Form 6-K Grifols SA For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +0.21% | |
| Form 6-K Grifols SA For: Mar 10 | SEC filing · Form 6-K | SEC EDGAR | +0.25% | -3.52% | |
| Form 6-K Grifols SA For: Feb 27 | SEC filing · Form 6-K | SEC EDGAR | +0.37% | +4.58% | |
| Form 6-K Grifols SA For: Feb 26 | SEC filing · Form 6-K | SEC EDGAR | +1.89% | +4.41% | |
| Form 6-K Grifols SA For: Feb 25 | SEC filing · Form 6-K | SEC EDGAR | +0.30% | -1.30% | |
| Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease | Press release | GlobeNewswire | +0.00% | -2.62% | |
| Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols | Press release | Business Wire | +0.00% | +2.26% | |
| Form 6-K Grifols SA For: Dec 23 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.09% | |
| Form 6-K Grifols SA For: Dec 12 | SEC filing · Form 6-K | SEC EDGAR | -0.13% | +1.85% | |
| Form 6-K Grifols SA For: Dec 09 | SEC filing · Form 6-K | SEC EDGAR | +0.43% | -1.10% | |
| Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga | Press release | Business Wire | -0.28% | +1.53% | |
| Form 6-K Grifols SA For: Nov 27 | SEC filing · Form 6-K | SEC EDGAR | +1.56% | -1.13% | |
| Form 6-K Grifols SA For: Nov 19 | SEC filing · Form 6-K | SEC EDGAR | +1.15% | +2.17% | |
| Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors | Press release | Business Wire | +1.15% | +2.17% | |
| Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors | Press release | Business Wire | -0.84% | -0.63% | |
| Form 6-K Grifols SA For: Nov 07 | SEC filing · Form 6-K | SEC EDGAR | -1.11% | +0.37% | |
| Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution | Press release | GlobeNewswire | -0.23% | -5.86% | |
| Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury | Press release | GlobeNewswire | -0.12% | +1.26% | |
| GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat | Press release | GlobeNewswire | +0.69% | +2.40% | |
| Form 6-K Grifols SA For: Sep 25 | SEC filing · Form 6-K | SEC EDGAR | +0.23% | -1.24% | |
| Form 6-K Grifols SA For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | -0.35% | +0.58% | |
| GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339 | Press release | GlobeNewswire | +0.00% | -5.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GRFS section they belong to.
Where else GRFS is measured.
GRFS earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Repligen Corporation (RGEN) | 301 | +0.15% | 55% |
| EIDOS THERAPEUTICS (EIDX) | 300 | +0.01% | 51% |
| Sangamo Therapeutics, Inc. (SGMO) | 300 | -0.55% | 38% |
| Merit Medical Systems, Inc. (MMSI) | 299 | -0.03% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Grifols, S.A. - American Depositary Shares's median reaction calculated?
Every labeled GRFS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 300 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 39% of GRFS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GRFS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.